Purpose This study examined whether a CYP2D6 polymorphism (CYP2D6*4) was related to beta-blocker maintenance dose in patients with heart failure. Methods Logistic regression modeling was utilized in a retrospective chart-review analysis of heart-failure patients (60% Male, 90% of European descent) to assess whether CYP2D6*4 (non-functional CYP2D6 allele present in 1 of 5 individuals of European descent) is associated with maintenance dose of carvedilol (n = 65) or metoprolol (n = 33). Results CYP2D6*4 was associated with lower maintenance dose of metoprolol (OR 0.13 [95% CI 0.02-0.75] p = 0.023), and a trend was observed between CYP2D6*4 and higher maintenance dose of carvedilol (OR 2.94 [95% CI 0.84-10.30] p = 0.093). None of the patients that carried CYP2D6*4 achieved the recommended target dose of metoprolol (200 mg/day). Conclusion Consistent with the role of CYP2D6 in the metabolism of metoprolol, the tolerated maintenance dose of metoprolol was lower in CYP2D6*4 carriers compared to non-carriers. Consistent with the role of CYP2D6 in activation of carvedilol, tolerated maintenance dose of carvedilol was higher in CYP2D6*4 carriers compared to non-carriers. Further investigation is warranted to ascertain the potential of CYP2D6 as a potential predictive biomarker of beta-blocker maintenance dose in heart failure patients.
INTRODUCTION
Heart failure is a major public health problem that impacts nearly 6 million Americans (1) . One in five Americans over the age of 40 years will develop heart failure during their lifetime, and one in five heart failure patients will die within 1 year of diagnosis (1) . Although heart transplantation is often the only Electronic supplementary material The online version of this article (doi:10.1007/s11095-017-2104-8) contains supplementary material, which is available to authorized users.
remaining intervention, there is a relative paucity of available donor hearts (<3,000 hearts were donated for transplantation in the United States in 2015) (2) . Beta-blockers are one of the few pharmacologic therapies that can significantly prolong survival for patients with heart failure. Accordingly, beta blockers are recommended for all patients with systolic heart failure (unless contraindicated) (3) . Unlike other indications for beta-blockers (e.g., hypertension or atrial fibrillation), efficacy has not been consistent among beta-blocker types in heart failure. In the United States, three beta-blockers are recommended for the treatment of heart failure: carvedilol, metoprolol, and bisoprolol (3) . While beta-blocker dose is titrated to response (e.g., target blood pressure or heart rate) for betablocker indications other than heart failure, the predictive value of these surrogate measures for efficacy in the treatment of heart failure has not been established. In treating heart failure, beta-blockers are titrated, therefore, to a target dose as reflected in the following treatment guideline issued by the American College of Cardiology and the American Heart Association for the treatment of heart failure: Clinicians should make every effort to achieve the target doses of the beta-blockers shown to be effective in major clinical trials (3) . The doses shown to be effective were 50, 80, and 200 mg/day for carvedilol, controlled-release carvedilol, and metoprolol succinate or tartrate, respectively (3) .
Nearly 85% of heart failure patients achieved recommended doses of beta-blockers in the reported clinical trials of betablocker efficacy (3) . Only half of patients, however, achieve target doses in clinical practice (4) . Dose-limiting adverse effects (e.g., bradycardia, hypotension, or fatigue) are the primary impediment (4) . Occurrence and/or severity of adverse effects are likely influenced by altered systemic drug exposure secondary to concomitant medication use, diseased states or genetic polymorphisms. As both metoprolol and carvedilol are metabolized by cytochrome P450 2D6 (CYP2D6) (5-7) and CYP2D6 is highly polymorphic causing extreme phenotypic variability resulting in CYP2D6 ultra-rapid, extensive, intermediate, and poor metabolizer (UM, EM, IM, and PM, respectively) phenotypes (8) , genetic status of CYP2D6 may be a determinant of beta-blocker tolerability. Importantly, functional polymorphisms in CYP2D6 are common, with the decrease-of-function CYP2D6*10 allele present in nearly 40% of patients with Asian ancestry and the *4 nonfunctional allele present in nearly 20% of patients with European ancestry (8) .
Much of the reported research on the effects of CYP2D6 genetic polymorphisms on beta-blockers involved data collected in late-phase (efficacy) clinical trials (6,9-13) or highly controlled early-phase (pharmacokinetics) clinical studies (5, (14) (15) (16) (17) . The reported findings from those studies, therefore, may not be generalizable to patients under routine clinical care. Moreover, most of the previous research on CYP2D6 and beta-blockers was not conducted specifically in patients with heart failure. As a result, physiologic changes associated with heart failure (e.g., edema, hepatocellular damage, hypoxia, and elevated levels of pro-inflammatory cytokines) are neglected despite their potential to dramatically alter betablocker pharmacokinetics. Total hepatic cytochrome P450 content is decreased by about 40% (18) and the oral areaunder-the-concentration-time curve for many drugs is increased by nearly 50% in patients with heart failure (19) . Given these substantial changes associated with heart failure and notable differences between routine clinical practice and controlled clinical trials, this study of the association between CYP2D6 and beta-blocker maintenance dose in heart failure patients receiving routine clinical care at a large academic medical center is critical to pharmacogenetics and precision medicine research. As this study cohort was comprised largely of patients with European ancestry, this analysis focused on CYP2D6*4 (the most common non-functional allele in individuals with European ancestry) to assess whether CYP2D6 is associated with beta-blocker maintenance dose in patients with heart failure. In addition, three CYP2D6 genotypemetabolizer phenotype classification schemes (based on CYP2D6*4 status) are presented and compared.
MATERIALS AND METHODS

Patient Data
This study was a retrospective chart review of 102 patients with systolic heart failure that participated in the Ohio State University-Coriell Personalized Medicine Collaborative (OSU-CPMC). The OSU-CPMC has been described in detail previously (20) . Briefly, the parent CPMC study sought to understand best practices regarding the use of genomic information in medical settings and in individual health management within three distinct study cohorts: community, cancer, and chronic disease. The community cohort participants were recruited without regard to health status or affiliation with a healthcare institution, while the cancer cohort consisted of participants with a personal history of either breast or prostate cancer. The OSU site within the parent CPMC study specifically focused on the chronic disease cohort. Systolic heart failure and hypertension were the two chronic diseases chosen as foci for the chronic disease cohort. Through the identification of clinical champions, OSU physicians were directly involved in the recruitment of patients from OSU Primary Care Clinics, the Ross Heart Hospital and ambulatory care clinics, and the University Hospital East Cardiology Clinic. For the heart failure cohort, inclusion criteria included a documented age of 18 years or older and documented diagnoses (ICD-9 code in their EPIC® electronic medical record, EMR) of systolic heart failure. Dedicated study recruiters worked closely with physicians on the heart failure service at the Ross Heart Hospital to ensure that only patients with systolic heart failure were enrolled. Demographics, vital signs, vital status, diagnosis codes, anthropometric measurements, and detailed medication history including specific drugs, drug doses, dosing frequencies, and drug start/stop dates were collected from the EMR via the OSU Information Warehouse; data was collected for each patient from the first available entry (OSU medical center initiated Epic EMR in 2008) through July 14, 2014.
Medication profiles were reviewed by a board-certified Pharmacotherapy Specialist, and the number of days each patient was prescribed specific beta-blocker doses was counted utilizing the prescription start and stop dates documented in the EMR. For this investigation, beta-blocker maintenance dose was defined as the dose prescribed for the longest period within the available EMR time window, and patients were considered to have reached their target dose only if their prescribed beta-blocker maintenance dose was at least as high as the guideline-recommended target dose (50, 80, and 200 mg/ day of carvedilol, controlled-release carvedilol, and metoprolol succinate or tartrate, respectively) (3) . No patients in this study were treated with bisoprolol or other beta-blockers. For this analysis, metoprolol dose was normalized to carvedilol dose by dividing the metoprolol dose by 4. This normalization was based on the mean doses achieved in clinical trials (37 mg/day for carvedilol and 159 mg/day for metoprolol) (3) and is consistent with both the recommended target doses of carvedilol and metoprolol (i.e., the target dose for metoprolol is 4 times greater than for carvedilol) and with the normalization utilized in previous studies comparing carvedilol and metoprolol in patients with heart failure (21). EMRs were also evaluated for the number of concomitant medications known to interact with metoprolol or carvedilol (online supplemental Table V and Table VI , respectively). Medications with potential to increase or decrease beta-blocker exposure or effect (via inhibition or induction of CYP2D6 metabolism, respectively) were tabulated and included in covariate-adjusted models. For clinical characteristics with temporal variation (e.g., body mass index, systolic blood pressure), averages (during the period beta-blocker maintenance dose data were collected) were calculated and included in covariate-adjusted models.
Genotyping and Phenotyping
DNA isolation and genotyping were performed by the Coriell Genotyping and Microarray Center at the Coriell Institute for Medical Research, a Clinical Laboratory Improvement Amendments (CLIA)-certified facility. DNA was isolated from saliva samples per standard protocols and genotyped using the Affymetrix DMET™ Plus Premier Pack. The Affymetrix DMET™ Plus Premier Pack covers 31 polymorphisms in CYP2D6 and translates them into the *star allele nomenclature using standard annotation (specific markers in file version BDMET_Plus.v1.20120731.dc_annot^call *star alleles d e t a i l e d a t h t t p : / / w w w . a f f y m e t r i x . com/support/technical/byproduct.affx?product=dmet_2). Notably, this method cannot reliably detect increased copy number of CYP2D6 (i.e., UM phenotype [UM]) or the *5 deletion). The Pharmacogenomics Advisory Group of the CPMC has recommended adding a specific, copy number variation assay to the DMET Plus array, but this assay had not been implemented at the time of this study. CYP2D6 metabolizer phenotype was estimated from genotypes using three approaches: *4 alone (rs3892097 G>A) and using multiple *star alleles with definitions according to the Pharmacogenomics Knowledgebase (PharmGKB®) (22) and to the Dutch Pharmacogenetics Working Group (DPWG) definition (23) . These three approaches are described in Table I . CYP2D6*4 was the only allele included in this analyses for reasons of logistical simplicity and because it is the most common non-functional CYP2D6 polymorphism in individuals with European descent. Furthermore, the use of a single genetic variant (CYP2D6*4) as a predictive biomarker could facilitate more rapid clinical implementation with lower costs compared to multi-variant arrays requiring more complex models (e.g., the PharmGKB® and DPWG models) that still only partially account for CYP2D6 metabolizer variability. Moreover, CYP2D6*4 alone identifies the majority of PM (8) . Due to its complexity, substrate specificity and current lack of a standard definition, the CYP2D6 activity score (genotypebased CYP2D6 phenotype estimates from analyses utilizing probe substrates such as dextromethorphan, codeine and various-depressants) (24) was not used in this analysis.
Statistical Analysis
Continuous variables were summarized by median ± interquartile range and were compared by the number of *4 alleles using the Kruskal-Wallis test. Categorical variables were summarized by counts and percentages and were compared by the number of *4 alleles using the χ 2 test or Fisher's exact test (when any expected value in the contingency tables was <5). Hardy-Weinberg equilibrium was assessed with the χ 2 test and the Monte Carlo estimate of the exact p-value using 10,000 permutations. The association between CYP2D6 metabolizer phenotypes (estimated from CYP2D6 genotypes) and betablocker maintenance dose was assessed using unadjusted and adjusted ordinal logistic regression models. Linear regression was not appropriate because the maintenance dose variable was not normally distributed (visual inspection of the distribution and Q-Q plots and a failed Kolmogorov-Smirnov goodness-of-fit test). Maintenance dose (in carvedilol dose equivalents) was categorized into 4 levels for ordinal logistic regression modeling: level 1 ≤ 6.25 mg/day (n = 17); level 2 = 12.5 mg/day (n = 18); level 3 = 20-25 mg/day (n = 20); and level 4 ≥ 50 mg/day (n = 47). This categorization scheme met the assumption for proportional odds (score test with chi-square distribution p > 0.05), and the adjusted models included the following covariates: age, body mass index, gender, selfreported race, and the number of drugs with major interactions with the beta-blocker. Statistical analyses were performed using SAS version 9.3, and p < 0.05 was considered statistically significant.
RESULTS
The genotyping call rate for *4 (rs3892097 G>A) was 100% (n = 102) and within Hardy Weinberg equilibrium (p > 0.05 via χ 2 and exact tests). The minor allele frequencies of *4 were 0.17 and 0.10 in the patients with self-reported European ancestry (n = 89) and with self-reported African ancestry (n = 10), respectively. These were consistent with the population minor allele frequencies reported in 1000 genomes for European and African populations (0.19 and 0.06, respectively). PharmGKB®-and DPWG-defined CYP2D6 metabolizer phenotypes were called in 99% of patients (n = 101). The numbers in each CYP2D6 metabolizer phenotype group (categorized according to the three CYP2D6 metabolizer phenotype classification schemes) are presented in Fig. 1 , and all classification schemes defined the same 2 patients as PM, but the numbers of EM and IM patients differed among the metabolizer classification schemes. The DPWG scheme identified the highest number of patients as IM (n = 33), and the PharmGKB® definition identified the least IM (n = 11). Using *4 alone to classify CYP2D6 metabolizer phenotype status yielded very similar grouping as compared to utilization of the DPWG classification scheme. The numbers of IMs varied by only 5 (28 vs. 33 using *4 alone and DPWG, respectively). The median duration of the EMR time window analyzed was 5.3 years (range 2.0-6.3 years).
Patient demographics and clinical variables were stratified by number of *4 alleles (Table II) , and no significant associations were determined for those variables. Only 23 patients (23%) were prescribed beta-blocker dose(s) higher than the dose determined to be their maintenance dose (i.e., the dose they were prescribed for the longest duration within the time period their EMR was examined), and in those 23 patients the mean duration of treatment at the maximum dose was 348 days compared to 923 days at the dose determined to be their maintenance dose. This relatively low percentage (23%) of patients and the significantly shorter (3-fold) duration suggest our method for determining maintenance dose was reasonable. The schedule for beta-blocker dose titration utilized in the published clinical trials followed a doubling of the dose every 14 days as tolerated by the patient (25) . In clinical practice, however, a 14-day beta-blocker titration is rarely adequate. Fortunately, the lengthy duration of EMR records examined for this study likely provided ample time for multiple dose titrations. No concomitant medications with potential to decrease beta-blocker exposure or effect were identified in any of the patient's medication profiles. The drug-drug interaction variable, therefore, reflected only drug-drug interactions known to increase beta-blocker exposure or effect. Importantly, no individual patient was prescribed more than one interacting concomitant medication during the examined time period of beta-blocker treatment.
Beta-blocker-type (carvedilol and metoprolol) interactions (beta-blocker-type*CYP2D6 metabolizer phenotype) with CYP2D6 metabolizer phenotype were statistically significant (p = 0.003 for specific beta-blocker*CYP2D6 phenotype interaction in covariate-adjusted model of *4 alone metabolizer definition, p = 0.015 in unadjusted model of *4 alone metabolizer definition, and p < 0.05 for PharmGKB® and DPWG metabolizer definitions as well), indicating the effect (Table III) did not vary significantly between carvedilol-and metoprolol-treated groups. However, the following observations were apparent: carvedilol-treated patients reached significantly higher maintenance doses compared to those treated with metoprolol (median normalized dose of 50 mg/day vs. 12.5 mg/day), the duration of treatment at maintenance dose was longer for carvedilol-treated patients compared to those treated with metoprolol (median 3.1 vs. 1.7 years), and the percentage of patients that reached guideline-recommended target maintenance doses was higher in carvedilol-treated patients compared to those treated with metoprolol (70% vs. 12%).
The following relationships (Fig. 2) were observed in analyses (co-variate adjusted) of CYP2D6 metabolizer phenotype (defined by *4 alone) and maintenance dose of carvedilol or Table I ): *4 (rs3892097 G>A) alone, and using multiple *star alleles with the Pharmacogenomics Knowledgebase (PharmGKB®) definition (22) 
DISCUSSION
The beta-blocker treatment strategy for patients with systolic heart failure is unique: treatment is titrated to a target dose rather than a target effect. This Bone size fits all^treatment strategy (uniform target dose for all patients with systolic heart failure) is inconsistent with the goal of precision medicine (e.g.,
Bthe right dose for each individual patient^) (26) . In this study, CYP2D6 metabolizer phenotype was significantly associated with the maintenance dose of metoprolol in patients with heart failure. Regardless of CYP2D6 metabolizer phenotype classification scheme (*4 alone, PharmGKB®, or DPWG), no patients with CYP2D6 PM or IM status reached the guideline-recommended (3) target doses of metoprolol. Acknowledging the small sample size and retrospective design of this study, the results suggest potential for a novel implementation of precision medicine: tailoring metoprolol target dose based on CYP2D6 status. Results from this study were consistent with the known role of CYP2D6 in the metabolism of metoprolol, suggesting that tolerated maintenance doses may be lower for CYP2D6 PM or IM compared to EM. Studies in additional cohorts are warranted to substantiate this finding.
As expected, the associations of CYP2D6 metabolizer phenotype with metoprolol and carvedilol maintenance doses had opposite directions. A decrease in CYP2D6 metabolic capacity (predicted from CYP2D6*4 genetic status) was associated with lower maintenance dose of metoprolol (p = 0.023), and a trend was observed between CYP2D6*4 and higher maintenance dose of carvedilol (p = 0.093). The different strengths and directions of these associations are consistent with the known differences in CYP2D6 metabolism of metoprolol and carvedilol. Metoprolol is administered as a racemic mixture of R-and S-enantiomers, both of which are primarily metabolized by CYP2D6 to inactive metabolites (27) . Carvedilol is also administered as a racemic mixture and metabolized by CYP2D6. However, CYP2C9 also plays a major role in the metabolism of carvedilol (28), potentially accounting for the weaker strength of the relationship of CYP2D6 with carvedilol compared to metoprolol. More importantly, carvedilol is metabolized to active metabolites by CYP2D6 (including a metabolite that is 13 times more potent than the parent carvedilol) (28) , and metoprolol is metabolized to inactive metabolites by CYP2D6, accounting for the opposite directions of the observed associations. Patients treated with metoprolol and with decreased CYP2D6 activity would be expected to have decreased metabolism of the active, parent metoprolol to inactive metabolites, and thus they would have tolerate lower maintenance dose of metoprolol. In contrast, patients treated with carvedilol and with decreased CYP2D6 activity would be expected to have decreased activation of the parent carvedilol and would, therefore, tolerate higher maintenance dose of carvedilol. The previous literature supports significant effects of CYP2D6 genetic polymorphisms on the pharmacokinetics of metoprolol (14) and carvedilol (5, (15) (16) (17) 29, 30) , but clinical significance has remained uncertain. Although several studies have found a significant association between CYP2D6 genetic polymorphisms and beta-blocker dose or patient response to metoprolol or carvedilol (6, (10) (11) (12) (31) (32) (33) (34) (35) (36) (37) (38) (39) , an almost equal n u m b e r o f s t u d i e s h a v e r e p o r t e d n u l l f i n d i n g s (9, 11, 13, 32, (40) (41) (42) (43) (44) . Our findings regarding carvedilol dose are consistent with the reported findings of Baudhuin et al. (31) . They determined that CYP2D6 PM with heart failure tolerated significantly higher doses of carvedilol than CYP2D6 EM and IM. Shihmanter et al., however, did not find a significant association between carvedilol dose and CYP2D6 polymorphisms in their retrospective chart review of patients with heart failure (45). The reasons for discordance among the study results are not clear, but differences regarding the carvedilol doses utilized may have been an important factor. The average treatment dose of carvedilol in this study and in the study reported by Baudhuin et al. were about 2-fold higher compared to those in the study reported by Shihmanter et al. (45-50 mg/day vs. 22 mg/day). This suggests the effects of CYP2D6*4 on carvedilol dose may become apparent in only higher dose ranges. Importantly, the higher carvedilol doses in this study and the study reported by Baudhuin et al. are more consistent with the guidelinerecommended target dose of carvedilol (50 mg/day) (3).
Our findings regarding metoprolol maintenance dose are consistent with conclusions reported in two previous studies. In the prospective, double-blind, longitudinal study reported by Rau et al., metoprolol dose escalation was tolerated in only 6% of CYP2D6 PM compared to 20% of CYP2D6 non-PM (6). In the largest study to date of CYP2D6 genetic polymorphisms and beta-blocker effects (n = 1,533 total with n = 513 metoprolol treated), Bijl et al. reported that CYP2D6 PM were treated with significantly lower doses of metoprolol (38) and that CYP2D6*4 was significantly associated with heart rate, bradycardia, and diastolic blood pressure in patients treated with metoprolol (38) . In contrast to our findings and those reported by Rau et al. and Bijl et al., Batty et al. did not find a significant association between CYP2D6*4 and metoprolol dose in their pharmacogenetic sub-study of the MERIT-HF trial (11) . As the study reported only on the association of CYP2D6*4 and clinical outcomes, the study reported by Batty et al. did not find significant differences among CYP2D6*4 genotypes in all-cause mortality or rate of hospitalization (11) . The lack of association between CYP2D6*4 and clinical outcomes reported by Batty et al. may have been secondary to an inherent decrease in statistical power (decreased sample size and increased number of comparison groups) characteristic of retrospective genetic sub-study analyses. Less than 10% of the patients from the overall MERIT-HF trial were included in the pharmacogenetic sub-study (n = 313 in the pharmacogenetic sub-study vs. n = 3,991 in the overall trial). Moreover, the randomized clinical trial design does not reflect beta-blocker treatment in routine clinical practice. Approximately 85% of heart failure patients achieved the target doses of beta-blockers in randomized clinical trials (3), but only approximately 50% do in clinical practice (4) .
When baseline and clinical variables were stratified by beta-blocker type, carvedilol-treated patients reached significantly higher maintenance doses compared to those treated with metoprolol, the duration of treatment at maintenance dose was longer for carvedilol-treated patients compared to those treated with metoprolol, and the percentage of patients that reached guideline-recommended target maintenance doses were higher in carvedilol-treated patients compared to those treated with metoprolol. Our findings are consistent with a previous study by Pasternak et al. (21) , in which a higher proportion of carvedilol-treated heart failure patients reached guideline-recommended target doses than metoprolol-treated patients (52% vs. 12%, respectively) and the duration of treatment with carvedilol was longer than with metoprolol (2.3 years vs. 1.8 years). We speculate that these differences in dose titration and treatment duration may likely have been secondary to differences in the tolerability of carvedilol and metoprolol, potentially related to the larger role of CYP2D6 in the metabolism of metoprolol compared to carvedilol. This study had several strengths and limitations. The small sample size and limited recruitment pool (single academic medical center) as well as the nearly homogenous demographic background (90% of participants with European ancestry) limit the generalizability of our findings. Although focusing on CYP2D6*4 alone in this study provided several logistic advantages (described in BGenotyping and Phenotyping^section of Materials and Methods), this was a limitation of the study. Our comparison of three different approaches for defining CYP2D6 metabolizer phenotypes from CYP2D6*4 genotype was a unique strength of this study, but the CYP2D6 genotyping platform used in this study was not able to identify gene duplications, the *5 gene deletion, or other functional CYP2D6 polymorphisms. An additional weakness was that CYP2C9 genetic status was not accounted for in the analyses of carvedilol-treated patients.
The low number (n = 2) of patients categorized as CYP2D6 PM was another limitation. A strength of this study, however, was the long duration (median 5.3 years of EMR available). The retrospective chart review design was an additional strength because it provided a snapshot in time of real-world patients in routine clinical practice; however, the retrospective chart review design also resulted in additional limitations (e.g., incomplete documentation in EMR, unknown patient compliance, multiple individuals contributing to EMR). As no quantifiable inclusion criteria for heart failure patients were readily available for this study, ICD-9 codes in the EMR along with the clinical expertise of cardiology physician specialists were used to determine eligibility for inclusion in the study. The lack of quantifiable criteria for heart failure represents a weakness of this study. In addition, utilizing EMR data to assess maintenance dose, the primary endpoint, has limitations. Specifically, the EMR shows prescription data and not whether the patients filled the prescription or were adherent to the prescription. Lacking assessment of titration status is another limitation to utilizing the EMR in determining the maintenance dose achieved. Based on our clinical experience and the clinical guidelines (3), beta-blockers are initiated at the lowest dose and then titrated up (as tolerated by patient) to the guideline-recommended target dose. Common dose-limiting side effects include bradycardia, hypotension, or fatigue. Symptoms that would have presumably been related to beta-blocker titration, however, were not available in the EMR. In future studies, a prospective design would allow such data to be collected, providing increased confidence regarding the determination of patient's titration status. Another major limitation of this study was the unavailability of blood samples for measuring concentration levels of carvedilol and metoprolol. Those measurements would have provided an opportunity to validate the assumption that dose requirements were affected by differences in CYP2D6 metabolism. None the less, results of this study demonstrate that associations with CYP2D6 genotype depend upon the CYP2D6 phenotyping approach (i.e., the association for metoprolol was statistically significant when using the DPWG and *4 alone classification but not when using the PharmGKB® classification) and that CYP2D6*4 is associated with tolerated maintenance doses of metoprolol and carvedilol in patients with systolic heart failure.
CONCLUSIONS
The Bone size fits all^treatment strategy provided in the current recommendation guidelines for beta-blocker therapy in heart failure patients (the same target dose for all patients) is inconsistent with the tenets of precision medicine. The literature as a whole strongly supports that CYP2D6 genetic polymorphisms effect the pharmacokinetics of metoprolol and carvedilol, but a consensus has not yet been reached regarding whether those pharmacokinetic effects translate into clinically meaningful differences in clinical outcomes or whether CYP2D6 may have significant potential as a predictive biomarker for determining a patient's target beta-blocker maintenance dose. While acknowledging the small sample size and retrospective design, results from this study were consistent with the known role of CYP2D6 in the metabolism of metoprolol and the activation of carvedilol. Although many argue whether prospective, randomized clinical trial validation for every new personalized dosing strategy, especially for drugs already on the market, is feasible or warranted (46) (47) (48) , results from this study suggest CYP2D6 may have predictive value regarding tolerable maintenance doses of metoprolol or carvedilol.
